| Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) (NCT05196087) | University Health Network, Toronto | 2022-07-20 |
| Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis (NCT05406466) | Fudan University | 2022-07-15 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672) | Regeneron Pharmaceuticals | 2022-07-14 |
| Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. (NCT06321640) | European Institute of Oncology | 2022-07-08 |
| A Study of TRK-950 in Patients With Advanced Solid Tumors (NCT05423262) | Toray Industries, Inc | 2022-07-06 |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (NCT04897321) | St. Jude Children's Research Hospital | 2022-07-06 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701) | Pfizer | 2022-07-05 |
| Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) (NCT05403177) | University Health Network, Toronto | 2022-06-23 |
| VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer (NCT05592639) | University College, London | 2022-06-23 |
| MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer (NCT05620290) | Sunnybrook Health Sciences Centre | 2022-06-15 |
| A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors (NCT05366478) | Suzhou BlueHorse Therapeutics Co., Ltd. | 2022-05-30 |
| REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (NCT04913025) | University College, London | 2022-05-26 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) (NCT05340621) | OnKure, Inc. | 2022-05-11 |
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors (NCT07121829) | Day One Biopharmaceuticals, Inc. | 2022-05-02 |
| Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (NCT05270044) | Pierre Fabre Medicament | 2022-05-02 |
| A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (NCT05354102) | Biomica Ltd. | 2022-05-01 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors (NCT04751396) | M.D. Anderson Cancer Center | 2022-04-20 |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (NCT05229601) | HiFiBiO Therapeutics | 2022-04-20 |
| Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors (NCT05121545) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-04-06 |
| ERK Inhibitor JSI-1187 in Advanced Solid Tumors (NCT06239623) | JS InnoPharm, LLC | 2022-04-02 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma (NCT05130177) | Diwakar Davar | 2022-03-16 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (NCT05169437) | Tempus AI | 2022-03-15 |
| CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma (NCT05289193) | Memorial Sloan Kettering Cancer Center | 2022-03-11 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT05621837) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2022-03-10 |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (NCT05238883) | HiFiBiO Therapeutics | 2022-03-10 |
| A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma (NCT05234437) | QBiotics Group Limited | 2022-03-09 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (NCT05068102) | Boehringer Ingelheim | 2022-03-03 |
| Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (NCT05402059) | MelanomaPRO, Russia | 2022-03-02 |
| Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors (NCT05235607) | Sichuan University | 2022-03-01 |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors (NCT05302921) | Children's National Research Institute | 2022-02-18 |
| Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (NCT04955743) | Yale University | 2022-02-09 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (NCT05116202) | Hoffmann-La Roche | 2022-02-02 |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (NCT05863052) | University of Oklahoma | 2022-01-31 |
| To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma (NCT05106023) | Yong Chen | 2022-01-21 |
| Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (NCT04988841) | Assistance Publique - Hôpitaux de Paris | 2022-01-20 |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (NCT05260684) | Pfizer | 2022-01-17 |
| Education for Prevention of Melanoma in Hispanic Populations (NCT05388851) | Mayo Clinic | 2022-01-12 |
| Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NCT06116461) | Erasmus Medical Center | 2022-01-05 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (NCT04930783) | Dana-Farber Cancer Institute | 2022-01-03 |
| Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors (NCT03989050) | University of Cologne | 2022-01-01 |
| Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid (NCT05578820) | Gene Surgery LLC | 2022-01-01 |
| Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (NCT05117138) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2022-01-01 |
| Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (NCT05097378) | CCTU- Cancer Theme | 2022-01-01 |
| A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment (NCT03978611) | Bristol-Myers Squibb | 2021-12-09 |
| PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor (NCT05156515) | Peking University Cancer Hospital & Institute | 2021-12-09 |
| Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (NCT05013099) | ImaginAb, Inc. | 2021-12-09 |
| Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (NCT04961619) | Novartis Pharmaceuticals | 2021-12-01 |
| Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study (NCT05180851) | Shanghai Fengxian District Central Hospital | 2021-11-30 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma (NCT04572451) | Yana Najjar | 2021-11-29 |
| Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma (NCT02645149) | Melanoma Institute Australia | 2021-11-22 |
| Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer (NCT05027009) | OHSU Knight Cancer Institute | 2021-11-18 |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (NCT05108298) | Eastern Cooperative Oncology Group | 2021-11-10 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119) | Children's Oncology Group | 2021-11-08 |
| Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients (NCT07434323) | San Gallicano Dermatological Institute IRCCS | 2021-11-02 |
| PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation (NCT05089188) | University Hospital, Strasbourg, France | 2021-11-01 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Artificial Intelligence Augmented Training in Skin Cancer Diagnostics for General Practitioners (NCT04576416) | Herlev Hospital | 2021-11-01 |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma (NCT05104801) | Peking University Cancer Hospital & Institute | 2021-11-01 |
| Circulating Tumor DNA in Melanoma Patients (NCT07422805) | Institute of Oncology Ljubljana | 2021-11-01 |
| Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma (NCT05105100) | University of California, San Francisco | 2021-10-29 |
| A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (NCT05091346) | Eisai Inc. | 2021-10-27 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537) | Pfizer | 2021-10-20 |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (NCT05002569) | Bristol-Myers Squibb | 2021-10-19 |
| To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma (NCT05051865) | Peking University Cancer Hospital & Institute | 2021-10-09 |
| Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma (NCT05714371) | Novartis Pharmaceuticals | 2021-10-02 |
| pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE (NCT05171374) | MelanomaPRO, Russia | 2021-09-30 |
| Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy (NCT04899492) | Institut Cancerologie de l'Ouest | 2021-09-29 |
| Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (NCT05003622) | Pierre Fabre Medicament | 2021-09-27 |
| A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer (NCT05053230) | Memorial Sloan Kettering Cancer Center | 2021-09-20 |
| Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study) (NCT04570722) | Duke University | 2021-09-20 |
| Family History App in Personalized Medicine (NCT04726319) | University of Toronto | 2021-09-20 |
| AI Augmented Training for Skin Specialists (NCT04758988) | Herlev Hospital | 2021-09-15 |
| Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (NCT04899908) | Brigham and Women's Hospital | 2021-09-15 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy (NCT05077137) | Duke University | 2021-09-07 |
| HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation (NCT05263453) | Shanghai Kechow Pharma, Inc. | 2021-09-06 |
| Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (NCT05060432) | iTeos Belgium SA | 2021-09-06 |
| Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations (NCT05103891) | Pierre Fabre Medicament | 2021-09-03 |
| Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors (NCT05148325) | Bio-Thera Solutions | 2021-09-02 |
| MElanoma Research Lymph Node Prediction Implementation National_001 (NCT04759781) | SkylineDx | 2021-08-25 |
| Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study (NCT05223218) | Namida Lab | 2021-08-25 |
| A Study of PRT1419 in Patients With Advanced Solid Tumors (NCT04837677) | Prelude Therapeutics | 2021-08-11 |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042) | Simcha IL-18, Inc. | 2021-08-06 |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (NCT04913285) | Pierre Fabre Medicament | 2021-08-04 |
| Axitinib + Ipilimumab in Advanced Melanoma (NCT04996823) | H. Lee Moffitt Cancer Center and Research Institute | 2021-08-04 |
| Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients (NCT05054062) | Zuyderland Medisch Centrum | 2021-08-01 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors (NCT04985604) | Day One Biopharmaceuticals, Inc. | 2021-07-15 |
| Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma (NCT04979585) | Di Wu | 2021-07-15 |
| Integrated Basic Science Within the Instructional Design of Pattern Recognition Training (NCT05087485) | Herlev Hospital | 2021-07-10 |
| Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets (NCT04899921) | Dana-Farber Cancer Institute | 2021-06-30 |
| Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study (NCT05817149) | Aalborg University Hospital | 2021-06-22 |
| SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (NCT04929353) | University Of Perugia | 2021-06-20 |
| Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (NCT04498767) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-06-10 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |